|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||205.47 - 207.25|
|52-week range||166.56 - 247.57|
|Beta (5Y monthly)||1.39|
|PE ratio (TTM)||0.37|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
IQVIA Holdings' (IQV) enormous treasure trove of information is a distinguishing asset and also perhaps a big barrier to entry for competitors.
The stock is trading at a high multiple despite revenue that's growing by mid-single-digit percentages.
A strong database of patient records and a huge market are tailwinds for IQVIA's (IQV) success.
Trane Technologies, IQVIA Holdings and TuSimple Holdings are part of the Zacks Industry Outlook article.
The Zacks Technology Services industry seeks to benefit from increased digitization and dependency on technology, and the growing adoption of the multi-cloud model. TT, IQV and TSP are well-positioned to witness a demand surge.
IQVIA Holdings (IQV) first-quarter 2023 revenues improve year over year.
IQVIA (IQV) delivered earnings and revenue surprises of 1.66% and 1.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
IQVIA's (IQV) first-quarter 2023 revenues are expected to have increased year over year.
Market size and data reserve are positives for IQVIA Holdings (IQV). Foreign currency risk is bothersome.
According to the National Center for Advancing Translational Sciences, the average period from therapy discovery to Food and Drug Administration (FDA) approval is 14 years and costs $1 billion. Clinical research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are growing because the increasing price of developing, testing, manufacturing, and marketing therapies has made it more important that pharmaceutical companies speed the process along with fewer failures. Rather than doing all the clinical trial work or manufacturing work in-house, more healthcare companies are turning to CROs and CDMOs to reduce overhead and expedite bringing therapies to market.
IQVIA Holdings Inc. ( NYSE:IQV ) shareholders might be concerned after seeing the share price drop 11% in the last...
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
For investors looking to double their money, look for healthcare stocks that are consistently increasing revenue and earnings per share (EPS). Cigna Group (NYSE: CI), Danaher (NYSE: DHR), and IQVIA Holdings (NYSE: IQV) all have managed to generate double-digit (or higher) increases in either quarterly revenue and earnings per share, or both, over the past five years. Let's find out a bit more about these three growth stocks.
Fidelity National's (FIS) fourth-quarter results reflect sound contributions from its Banking and Capital Markets businesses. Management announces plan to spin off its Merchant Solutions unit.
IQVIA Holdings ( NYSE:IQV ) Full Year 2022 Results Key Financial Results Revenue: US$14.4b (up 3.9% from FY 2021). Net...
IQVIA (IQV) fourth-quarter 2022 earnings and revenues surged year over year.
IQVIA (IQV) delivered earnings and revenue surprises of 1.09% and 0.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
The shares for Doximity (NYSE: DOCS), Iqvia Holdings (NYSE: IQV), and TransMedics Group (NASDAQ: TMDX) are all off to positive starts this year, but what makes them different from other companies is that they are changing healthcare industry standards. Doximity is becoming a must for physicians thanks to its helpful applications. While technology has been a big part of medicine for a long time, the actual connection between doctors and patients is still stuck in the last century, with 80% of all healthcare documents sent by regular mail or fax.
IQVIA (IQV) fourth-quarter 2022 earnings and revenues are likely to have surged year over year.
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA Holdings Inc. ( NYSE:IQV ) received a lot of attention from a substantial price increase on the NYSE over the...
Symbotic Inc. (SYM) delivered earnings and revenue surprises of -140% and 4.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Seagate (STX) delivered earnings and revenue surprises of 45.45% and 3.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
The stocks for healthcare companies IQVIA Holdings (NYSE: IQV) and Vertex Pharmaceuticals (NASDAQ: VRTX), for example, have been on the upswing recently thanks to reports of increased revenues, rising earnings, and management outlooks that point to more growth on the way. IQVIA's shares were down more than 18% over the past year, but they're up more than 18% over the past three months. The company is starting to see volumes get back to normal now that the worst effects of the pandemic are fading.